

**Appendix Table. Characteristics of the Included Studies**

Author, Year (Reference)	Study Duration	Group	Patients, <i>n</i>	Mean Age, <i>y</i>	Men, %	Mean BMI (Body Weight), <i>kg/m<sup>2</sup> (kg)</i>	Mean Duration of Diabetes, <i>y</i>	Mean HbA <sub>1c</sub> or FG Level*	Previous Treatment, <i>n (%)</i>
<b>Randomized Controlled Trials</b>									
Abrahamian et al., 2005 (25)	24 weeks	Insulin aspart 70/30	89	62.6	52	28	12.7	HbA <sub>1c</sub> , 9.8%	Insulin naive: No
		NPH/regular 70/30	88	62.3	35	28.3	9.5	HbA <sub>1c</sub> , 9.85%	Insulin naive: No
Bebakar et al., 2007 (19)	24 weeks	Insulin aspart 70/30 + OAAs	128	55	92	26.2	4.4	HbA <sub>1c</sub> , 8.6%	Insulin naive: Yes OAAs: 128 (100)
		OAAs	63	52.7	69	25.4	4.3	HbA <sub>1c</sub> , 8.5%	Insulin naive: Yes OAAs: 63 (100)
Boehm et al., 2004 (28); Boehm et al., 2002 (73)‡	104 weeks	Insulin aspart 70/30	58	62.8	55 <sup>†</sup>	29.1	15.5	HbA <sub>1c</sub> , 8.11%	Insulin naive: No
		NPH/regular 70/30	67	62.6	51 <sup>†</sup>	27.2	12.9	HbA <sub>1c</sub> , 8.21%	Insulin naive: No
Christiansen et al., 2003 (32)	16 weeks	Insulin aspart 70/30	201	59.3	47	28	9.2	HbA <sub>1c</sub> , 8.8%	Insulin: 66 (33) OAAs: 78 (39) Insulin and OAAs: 55 (27)
		NPH insulin	202	59.6	50	28.4	10.5	HbA <sub>1c</sub> , 8.8%	Insulin: 66 (33) OAAs: 75 (37) Insulin and OAAs: 59 (29)
Herz et al., 2002 (34)	16 weeks	Insulin lispro 75/25	71	68.1	52.1	28	11.4	HbA <sub>1c</sub> , 9.82%	Insulin naive: No
		Glyburide	72	67.7	44.4	27.8	12.4	HbA <sub>1c</sub> , 9.9%	Insulin naive: No
Hirao et al., 2008 (40)	6 months	Insulin aspart 70/30	80	58.5	59 <sup>†</sup>	23.7 (62.5)	9.5	HbA <sub>1c</sub> , 10.5%	Insulin naive: No OAAs: 41 (51 <sup>†</sup> )
		Insulin aspart + NPH insulin	80	57.9	61 <sup>†</sup>	23.7 (62.1)	12.2	HbA <sub>1c</sub> , 10.7%	Insulin naive: No OAAs: 39 (49 <sup>†</sup> )

Holman et al., 2007 (9)	52 weeks	Insulin aspart 70/30**	235	61.7	67.7	30.2 (86.9)	9 median (IQR: 6 - 12)	HbA <sub>1c</sub> , 8.6%; FG, 175 mg/dL	Insulin naive: Yes OAs: 221 (94†)
		Insulin aspart**	238	61.6	63.6	29.6 (84.9)	9 median (IQR: 6 - 14)	HbA <sub>1c</sub> , 8.6%; FG, 173 mg/dL	Insulin naive: Yes OAs: 227 (95†)
		Insulin detemir**	234	61.9	61.9	29.7 (85.5)	9 median (IQR: 6 - 12)	HbA <sub>1c</sub> , 8.4%; FG, 171 mg/dL	Insulin naive: Yes OAs: 224 (96†)
		Total, 708		61.7	64.1	29.8 (85.8)	9 median (IQR: 6 - 13)	HbA <sub>1c</sub> , 8.5%; FG, 173 mg/dL	Insulin naive: Yes OAs: 672 (95†)
Kann et al., 2006 (22)	26 weeks	Insulin aspart 70/30 + metformin	128	61.5	54 <sup>†</sup>	29.9 (84.2)	10.3	HbA <sub>1c</sub> , 9.21%	NR
		Insulin glargine + glimepiride	127	61	49 <sup>†</sup>	30.6 (86.6)	10.2	HbA <sub>1c</sub> , 8.9%	NR
Kazda et al., 2006 (23)	24 weeks	Insulin lispro 50/50	54	58.7	59 <sup>†</sup>	31	5.9	HbA <sub>1c</sub> , 8.1%; FG, 167.4 mg/dL	Insulin naive: No Insulin: 0 in last 3 months
		Insulin lispro	52	60.4	62 <sup>†</sup>	31.7	5.3	HbA <sub>1c</sub> , 8.2%; FG, 176.4 mg/dL	Insulin naive: No Insulin: 0 in last 3 months
		Insulin glargine	53	59.1	43 <sup>†</sup>	30.1	5.5	HbA <sub>1c</sub> , 8.1%; FG, 172.8 mg/dL	Insulin naive: No Insulin: 0 in last 3 months
Kilo et al., 2003 (33)	12 weeks	Insulin aspart 70/30¶	46	57.2	54	30.4	10.4	HbA <sub>1c</sub> , 9.5%; FG, 241.8 mg/dL	Insulin naive: Yes OAs: 46 (100)
		NPH insulin¶	47	55.1	40	30.4	10.7	HbA <sub>1c</sub> , 9.5%; FG, 242.7 mg/dL	Insulin naive: Yes OAs: 47 (100)
		NPH/regular 70/30¶	47	55.4	52	30.6	8.4	HbA <sub>1c</sub> , 9.3%; FG, 227.2 mg/dL	Insulin naive: Yes OAs: 47 (100)
Kvapil et al., 2006 (24)	16 weeks	Insulin aspart 70/30	107	55.2	47 <sup>†</sup>	30.9 (87.3)	8.2	HbA <sub>1c</sub> , 9.6%	Insulin naive: NR
		Insulin aspart 70/30¶	108	56.4	49 <sup>†</sup>	30.4 (85.1)	6.7	HbA <sub>1c</sub> , 9.3%	Insulin naive: NR
		Glibenclamide¶	114	58.1	46 <sup>†</sup>	30.5 (84)	8.1	HbA <sub>1c</sub> , 9.4%	Insulin naive: NR

Malone et al., 2003 (31)	16 weeks	Insulin lispro 75/25¶	296	58	57	29.8 (83)	8	HbA <sub>1c</sub> , 9.17%	Insulin naive: NR OAAAs: 296 (100)
		Glibenclamide¶	301	59	49	29.6 (81.7)	7.4	HbA <sub>1c</sub> , 9.27%	Insulin naive: NR OAAAs: 301 (100)
Nauck et al., 2007 (21)	52 weeks	Insulin aspart 70/30**	248	58	51	30.2 (83.4)	10	HbA <sub>1c</sub> , 8.6%; FG, 203.4 mg/dL	Insulin naive: NR OAAAs: 248 (100)
		Exenatide**	253	59	47	30.6 (85.5)	9.8	HbA <sub>1c</sub> , 8.6%; FG, 198 mg/dL	Insulin naive: NR OAAAs: 253 (100)
Raskin et al., 2005 (27); Brod et al., 2007 (74)	28 weeks	Insulin aspart 70/30‡‡	117	52.6	53	31.5 (90.6)	9.5	HbA <sub>1c</sub> , 9.7%; FG, 252 mg/dL	Insulin naive: Yes OAAAs: 117 (100)
		Insulin glargine‡‡	116	52.3	56	31.4 (89.9)	8.9	HbA <sub>1c</sub> , 9.8%; FG, 243 mg/dL	Insulin naive: Yes OAAAs: 116 (100)
Raskin et al., 2007 (72)§	28 weeks	Insulin aspart 70/30¶	79	52	51.9	31.2 (88.7)	NR	HbA <sub>1c</sub> , 9.9%; FG, 255.6 mg/dL	Insulin naive: Yes Insulin: 0 (0) OAAAs: 79 (100)
		Insulin glargine¶	78	51.7	53.8	30.8 (86.2)	NR	HbA <sub>1c</sub> , 9.9%; FG, 239.4 mg/dL	Insulin naive: Yes Insulin: 0 (0) OAAAs: 78 (100)
Raskin et al., 2007 (38)	34 weeks	Insulin aspart 70/30‡‡	102	53.4	45 <sup>†</sup>	32.4	9.2	HbA <sub>1c</sub> , 8.1%	Insulin naive: Yes OAAAs: 102 (100)
		Metformin + pioglitazone	98	54.2	39 <sup>†</sup>	33.4	8.3	HbA <sub>1c</sub> , 8.1%	Insulin naive: Yes OAAAs: 98 (100)
Raz et al., 2003 (30)	6 weeks	Insulin aspart 70/30§§	26	60.3	73.1	27.7	10.9	HbA <sub>1c</sub> , 9.9%; FG, 259.8 mg/dL	Insulin naive: NR OAAAs: 26 (100)
		Glibenclamide§§	23	57.8	56.5	27.6	10.3	HbA <sub>1c</sub> , 10.3%; FG, 265.2 mg/dL	Insulin naive: NR OAAAs: 23 (100)

Raz et al., 2005 (26)	18 weeks	Insulin aspart 70/30	97	55.2	65	29.5	10	HbA <sub>1c</sub> , 9.5%	Insulin naive: NR OAAAs: 97† (100)
		Insulin aspart 70/30	93	56.7	53	29.4	9.2	HbA <sub>1c</sub> , 9.6%	Insulin naive: NR OAAAs: 93† (100)
		Glibenclamide	91	55.8	62	29.5	9.9	HbA <sub>1c</sub> , 9.4%	Insulin naive: NR OAAAs: 91† (100)
Robbins et al., 2007 (37)	24 weeks	Insulin lispro 50/50 ¶	157	57.4	50.3	32.1 (89.1)	11.3	HbA <sub>1c</sub> , 7.8%	Insulin naive: No Insulin: 125 (79.6)
		Insulin glargine ¶	158	58.1	49.4	32 (88.1)	12.5	HbA <sub>1c</sub> , 7.8%	Insulin naive: No Insulin: 123 (77.8)
Rosenstock et al., 2008 (39)	24 weeks	Insulin lispro 50/50 ¶ ¶	187	55.4	53	34.1 (99.1)	10.9	HbA <sub>1c</sub> , 8.83%; FG, 171.81 mg/dL	Insulin naive: No Insulin: 187 (100) Insulin and OAAAs: 185 (98.9)
		Insulin glargine + insulin lispro ¶ ¶	187	54	52	34.8 (99.8)	11.2	HbA <sub>1c</sub> , 8.89%; FG, 181.48 mg/dL	Insulin naive: No Insulin: 187 (100) Insulin and OAAAs: 184 (98.5)
Tamemoto et al., 2007 (20)	24 weeks	Insulin aspart 70/30	14	55.9	54	23.9	9.8	HbA <sub>1c</sub> , 9.13%; FG, 183.3 mg/dL	Insulin naive: NR OAAAs: 14 (100)
		Insulin glargine	20	61.7	68	25.5	10.4	HbA <sub>1c</sub> , 8.45%; FG, 184.1 mg/dL	Insulin naive: NR OAAAs: 19 (100)
Tirgoviste et al., 2003 (29); Roach et al., 2001 (75)	16 weeks	Insulin lispro 75/25	85	58.7	35†	26.8 (74.1)	10.3	HbA <sub>1c</sub> , 9.85%; FG, 208.8 mg/dL	Insulin naive: Yes OAAAs: 85 (100)
		Glibenclamide	87	60.3	36†	27.6 (75.8)	10.2	HbA <sub>1c</sub> , 10.07%; FG, 219.6 mg/dL	Insulin naive: Yes OAAAs: 87 (100)
		Total, 172		59.5	35†	(75)	10.2	NR	Insulin naive: Yes OAAAs: 172 (100)

Ushakova et al., 2007 (36)	8 weeks titration; 8 weeks maintenance	Insulin aspart 70/30 3 times daily	104	58	16.3	29.8 (79.3)	9.9	HbA <sub>1c</sub> , 10.4%	Insulin naive: Yes OAs: 104 (100)
		Insulin aspart 70/30 twice daily + metformin	100	58.4	27	29.2 (78.4)	8.4	HbA <sub>1c</sub> , 10.4%	Insulin naive: Yes OAs: 100 (100)
		OAs	104	58.4	20.2	29.3 (78)	8.3	HbA <sub>1c</sub> , 10.1%	Insulin naive: Yes OAs: 104 (100)
Yamada et al., 2007 (35)	4 months	Insulin lispro 50/50	15	66	80 <sup>†</sup>	27	13.7	HbA <sub>1c</sub> , 7.59%; FG, 130.3 mg/dL	Insulin naive: No Insulin: 15 (100)
		NPH/regular 70/30 + NPH/regular 50/50	15	66.3	73 <sup>†</sup>	23.8	15.9	HbA <sub>1c</sub> , 7.33%; FG, 141.8 mg/dL	Insulin naive: No Insulin: 15 (100)
<b>Crossover Trials with No Washout Periods</b>									
Coscelli et al., 2003 (48)	12 days/period	Insulin lispro 75/25	18	59.1	39	29.5 (79)	14.9	FG, 154.2%	Insulin naive: No Insulin: 18 (100)
		NPH/regular 70/30	15	59.2	53	30.1 (80.2)	13.8	FG, 150.9 mg/dL	Insulin naive: No Insulin: 15 (100)
		Total, 33	33	59.1	45	29.8 (79.5)	14.4	FG, 152.5 mg/dL	Insulin naive: No Insulin: 33 (100)
Cox et al., 2007 (56)	12 weeks/period	Insulin lispro 75/25¶	28	NR	NR	NR	NR	NR	NR
		Insulin glargine¶	28	NR	NR	NR	NR	NR	NR
		Total, 45	45	52.6	NR	35.08	11.9	NR	Insulin naive: NR OAs: 45 (100)
Herz et al., 2002 (52)	4 weeks/period	Insulin lispro 75/25	19	56.3	63 <sup>†</sup>	27 (76)	8.9	NR	Insulin naive: No Insulin: 19 <sup>†</sup> (100)
		NPH/regular 70/30	18	55.3	33 <sup>†</sup>	26.3 (75.8)	7.5	NR	Insulin naive: No Insulin: 18 <sup>†</sup> (100)

Herz et al., 2003 (50)	4 weeks/period	Insulin lispro 75/25	13	54.8	77 <sup>†</sup>	29.2	NR	HbA <sub>1c</sub> , 7.81%	Insulin naive: No Insulin: 13 <sup>†</sup> (100)
		NPH/regular 70/30	12	53.6	58 <sup>†</sup>	29.3	NR	HbA <sub>1c</sub> , 7.6%	Insulin naive: No Insulin: 12 <sup>†</sup> (100)
Jacobber et al., 2006 (43)	16 weeks/period	Insulin lispro 75/25 + insulin lispro 50/50 <sup>††</sup>	59	NR	NR	NR	NR	NR	NR
		Insulin glargine <sup>††</sup>	59	NR	NR	NR	NR	NR	NR
		Total, 60		54.9	56.7	32.9 (95.1)	8.4	HbA <sub>1c</sub> , 9.21%	Insulin naive: Yes OAAAs: 60 (100)
Malone et al., 2004 (44)	16 weeks/period	Insulin lispro 75/25 <sup>¶</sup>	52	54.5	63.5	30.1 (88.5)	8.1	HbA <sub>1c</sub> , 8.7%; FG, 150.2 mg/dL	Insulin naive: Yes OAAAs: 52 (100)
		Insulin glargine <sup>¶</sup>	53	55.3	62.3	31.7 (94.4)	9.8	HbA <sub>1c</sub> , 8.7%; FG, 155.3 mg/dL	Insulin naive: Yes OAAAs: 53 (100)
Malone et al., 2005 (45)	16 weeks/period	Insulin lispro 75/25 <sup>¶</sup>	50	59.18	50	29.41 (77.82)	13.52	HbA <sub>1c</sub> , 8.5%; FG, 155.34 mg/dL	Insulin naive: No Insulin: 50 <sup>†</sup> (100) OAAAs: 26 (52 <sup>†</sup> )
		Insulin glargine <sup>¶</sup>	47	59.63	38	29.64 (77.21)	11.9	HbA <sub>1c</sub> , 8.48%; FG, 147.78 mg/dL	Insulin naive: No Insulin: 47 <sup>†</sup> (100) OAAAs: 28 (60 <sup>†</sup> )
Mattoo et al., 2003 (51)	2 weeks/period	Insulin lispro 75/25	72	54	47.2	26.9 (71)	13.2	NR	Insulin naive: No Insulin: 72 <sup>†</sup> (100)
		NPH/regular 70/30	79	52	44.3	26.5 (71)	11.8	NR	Insulin naive: No Insulin: 79 <sup>†</sup> (100)
		Total, 151		53	45.7	26.7 (71)	12.5	NR	Insulin naive: No Insulin: 151 <sup>†</sup> (100)

McNally et al., 2007 (41)	16 weeks/period	Insulin aspart 70/30	80	61.8	61 <sup>†</sup>	29.7 (83.3)	11.5	HbA <sub>1c</sub> , 7.5%	Insulin naive: No Insulin: 80 (100)
		NPH/regular 70/30	80	62.7	79 <sup>†</sup>	30.5 (89.1)	12.1	HbA <sub>1c</sub> , 7.5%	Insulin naive: No Insulin: 80 (100)
		Total, 160	62.3	70 <sup>†</sup>	30.1 (86.2)	11.8	HbA <sub>1c</sub> , 7.5%	Insulin naive: No Insulin: 160 (100)	
McSorley et al., 2002 (53)	2 weeks/period	Insulin aspart 70/30	13	NR	NR	NR	NR	NR	NR
		NPH/regular 70/30	13	NR	NR	NR	NR	NR	NR
		Total, 13	64	62 <sup>†</sup>	28.1	13	HbA <sub>1c</sub> , 7.7%	Insulin naive: No Insulin: 13 <sup>†</sup> (100)	
Niskanen et al., 2004 (46)	12 weeks/period	Insulin aspart 70/30	132	NR	NR	NR	NR	NR	NR
		Insulin lispro 75/25	132	NR	NR	NR	NR	NR	NR
		Total, 133	62.3	59 <sup>†</sup>	28.1	12.1	HbA <sub>1c</sub> , 8.5%	Insulin naive: No Insulin: 133 <sup>†</sup> (100)	
Roach et al., 1999 (54)	13 weeks	Insulin lispro 75/25	44	56.5	52 <sup>†</sup>	28.3	12.8	NR	Insulin naive: No Insulin: 44 <sup>†</sup> (100)
		NPH/regular 70/30	45	57.4	42 <sup>†</sup>	29.4	11.5	NR	Insulin naive: No Insulin: 45 <sup>†</sup> (100)
Roach et al., 1999 (55)	12 weeks/period	Insulin lispro 50/50 + insulin lispro 75/25	34	58	53 <sup>†</sup>	28.4	12.2	NR	Insulin naive: No Insulin: 34 <sup>†</sup> (100)
		NPH/regular 50/50 + NPH/ regular 70/30	29	60.2	41 <sup>†</sup>	28.4	13.1	NR	Insulin naive: No Insulin: 29 <sup>†</sup> (100)
Roach et al., 2003 (49)	8 weeks/period	Insulin lispro 75/25	57	53.9	40	62.8	12.4	NR	Insulin naive: No Insulin: 57 <sup>†</sup> (100)
		Insulin lispro 50/50 + insulin lispro 75/25	58	54.2	40	65.1	13.1	NR	Insulin naive: No Insulin: 58 <sup>†</sup> (100)

Roach and Malone, 2006 (42)	12 weeks/period	Insulin lispro 75/25††	20	NR	NR	NR	NR	NR	NR
		Insulin glargine††	20	NR	NR	NR	NR	NR	NR
		Total, 20	53.5	50	36.7 (108)	NR	HbA <sub>1c</sub> , 8.4%	Insulin naive: No	
Scherthauer et al., 2004 (47)	12 weeks/period	Insulin lispro 50/50	18	66.1	17†	29.5	16.2	HbA <sub>1c</sub> , 8.3	Insulin naive: No Insulin: 18† (100)
		NPH/regular 70/30	17	67.8	29†	28.8	14.2	HbA <sub>1c</sub> , 8.5%	Insulin naive: No Insulin: 17† (100)
		Total, 35	67	23†	29.2	15.3	NR	Insulin naive: No Insulin: 35† (100)	

#### Crossover Trials with Washout Period

Hermansen et al., 2002 (59)	1 day/period, washout period at least 5 days	Insulin aspart 70/30	41	NR	NR	NR	NR	NR	NR
		Insulin lispro 75/25	42	NR	NR	NR	NR	NR	NR
		NPH/regular 70/30	44	NR	NR	NR	NR	NR	NR
		Total, 61	60.1	66†	27.3	11.6	HbA <sub>1c</sub> , 8.3%	Insulin naive: No Insulin: 61† (100)	
Kapitza et al., 2004 (58)	1 day/period, washout period 3 – 21 days	Insulin aspart 70/30 (15 min. after test meal)	31	NR	NR	NR	NR	NR	NR
		Insulin aspart 70/30 (before meal)	31	NR	NR	NR	NR	NR	NR
		NPH/regular 70/30 (15 min. before test meal)	31	NR	NR	NR	NR	NR	NR
		NPH/regular 70/30 (before test meal)	31	NR	NR	NR	NR	NR	NR
		Total, 31	57	68†	29	12	HbA <sub>1c</sub> , 8.7%	Insulin naive: No Insulin: 31† (100)	

Malone et al., 2000 (60); Malone et al., 2000 (76)	1 day/period, washout period 3 – 11 days	Insulin lispro 75/25	41	59.2	63 <sup>†</sup>	29.1	14	NR	Insulin naive: No Insulin: 41 <sup>†</sup> (100)	
		NPH/regular 70/30	43	60.5	63 <sup>†</sup>	29.2	16.2	NR	Insulin naive: No Insulin: 43 <sup>†</sup> (100)	
		Total, 84		59.9	63 <sup>†</sup>	29.2	15.1	NR	Insulin naive: No Insulin: 84 <sup>†</sup> (100)	
Schwartz et al., 2006 (57)	1 day/period, washout period 3 – 11 days	Insulin lispro 50/50	7	NR	NR	NR	NR	NR	NR	
		Insulin lispro 75/25	8	NR	NR	NR	NR	NR	NR	NR
		NPH/regular	8	NR	NR	NR	NR	NR	NR	NR
		Total, 23		61.3	73.9	33 (98.5)	NR	HbA <sub>1c</sub> , 8.1%; FG, 158.7 mg/dL	Insulin naive: No Insulin: 23 (100)	
<b>Other Study Designs</b>										
Joshi et al., 2005 (17)	12 weeks	Insulin aspart 70/30	114	52.41	67 <sup>†</sup>	70.4	9.53	HbA <sub>1c</sub> , 8.79%; FG, 186.59 mg/dL	Insulin naive: NR Insulin: 62 (54.39) OAs: 102 (89.47)	
		Insulin aspart + insulin glargine	31	51.1	77 <sup>†</sup>	69.63	11.98	HbA <sub>1c</sub> , 8.53%; FG, 190.23 mg/dL	Insulin naive: NR Insulin: 21 (67.74) OAs: 25 (80.65)	
Sun et al., 2007 (18)	18 months	Insulin lispro 75/25	895	62.8	49.1	93.9	20.5	HbA <sub>1c</sub> , 8.6%	Insulin naive: Yes	
		Insulin glargine	3624	58.4	48.5	93.3	24.7	HbA <sub>1c</sub> , 8.6%	Insulin naive: Yes	
		NPH/regular 70/30	3647	65.7	44.7	92.3	18.3	HbA <sub>1c</sub> , 8.4%	Insulin naive: Yes	

BMI = body mass index; FG = fasting glucose; IQR = interquartile range; HbA<sub>1c</sub> = hemoglobin A<sub>1c</sub>; NPH = neutral protamine Hagedorn; NR = not reported; OAs = oral antidiabetic agents.

\*To convert glucose values from mg/dL to mmol/L, multiply by 0.0555.

<sup>†</sup>Number has been imputed.

<sup>‡</sup>The study population for was patients with either type 1 or type 2 diabetes. The type 2 diabetic population was the same as that used in reference 28. Boehm and colleagues (73) reported results after 12 weeks of follow-up.

<sup>§</sup>The study was conducted in a subpopulation of patients from reference 27 who were not using thiazolidinediones.

<sup>||</sup>The study group also received diet and exercise.

<sup>¶</sup>The study group also received metformin.

<sup>\*\*</sup>The study group also received metformin and a sulfonylurea.

<sup>††</sup>The study group also received oral antidiabetic agents.

<sup>‡‡</sup>The study group also received metformin and pioglitazone.

<sup>§§</sup>The study group also received rosiglitazone.

<sup>|||</sup>The study group also received pioglitazone.

<sup>¶¶</sup>The study group also received existing oral antidiabetic agents, except for sulfonylureas and glinides.

## References

73. **Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A.** Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. *Diabet Med.* 2002;19:393-9. [PMID: 12027927]
74. **Brod M, Cobden D, Lammert M, Bushnell D, Raskin P.** Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. *Health Qual Life Outcomes.* 2007;5:8. [PMID: 17286868]
75. **Roach P, Koledova E, Metcalfe S, Hultman C, Milicevic Z. Romania/Russia Mix25 Study Group.** Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. *Clin Ther.* 2001;23:1732-44. [PMID: 11726007]
76. **Malone JK, Yang H, Woodworth JR, Huang J, Campaigne BN, Halle JP, et al.** Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. *Diabetes Metab.* 2000;26:481-7. [PMID: 11173719]